Investments
662Portfolio Exits
114Funds
16Partners & Customers
1Service Providers
1About ARCH Venture Partners
ARCH Venture Partners is a provider of seed and early-stage venture capital for technology firms, with a special competence in co-founding and building firms from start-up. The firm's mission is to deliver promising technologies from the earliest stages to successful commercial application – from concept to commerce. ARCH Venture Partners was founded in 1986 and is based in Chicago, Illinois.
Want to inform investors similar to ARCH Venture Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing ARCH Venture Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find ARCH Venture Partners in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing ARCH Venture Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned ARCH Venture Partners in 7 CB Insights research briefs, most recently on Sep 19, 2022.
Latest ARCH Venture Partners News
May 25, 2023
News provided by Share this article Share this article CHICAGO, May 25, 2023 /PRNewswire/ -- ARCH Venture Partners today announced the appointment of life sciences industry veteran Kevin Hrusovsky as Venture Partner. "Kevin has been instrumental in the success of multiple ARCH portfolio companies, and we look forward to building the next generation of companies together," said ARCH Co-founder and Managing Director Keith Crandell. "ARCH is committed to bringing the best entrepreneurs, experience, value-add perspective, and network to advance our portfolio companies. Kevin has deep experience in the industry and is an important addition to the ARCH team." "I am excited to join ARCH as a Venture Partner. We share a common goal of building world-class life science companies to help improve the health and wellbeing of society. I am honored to join the ARCH team," said Hrusovsky. Hrusovsky has a 30-year career leading life sciences companies. He currently serves as Chairman of 908 Devices and previously held the roles of Executive Chairman, Chairman, and President and CEO at Quanterix (QTRX). Prior to Quanterix, he was CEO of Caliper Life Sciences (CALP – acquired by PKI), and Zymark Corp. (acquired by CALP), as well as President of Life Sciences at PerkinElmer (PKI). He also held senior roles at FMC Corp. and DuPont. In addition, he created Powering Precision Health foundation, an international non-profit promoting innovations to achieve precision medicine. He is regarded as a pioneering entrepreneur, accelerating adoption and value creation for technologies enabling drug development and disease prevention. Hrusovsky is the recipient of several distinguished awards including the 2019 New England EY Entrepreneur of the Year® and has been recognized for innovations in medicine and health. He holds an M.B.A. from Ohio University, a B.S. in mechanical engineering from The Ohio State University and an Honorary Doctorate from Framingham State University. About ARCH Venture Partners ARCH Venture Partners creates and invests in ground-breaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market. For more information, visit www.archventure.com . Contact:
ARCH Venture Partners Investments
662 Investments
ARCH Venture Partners has made 662 investments. Their latest investment was in Bitterroot Bio as part of their Series A on June 6, 2023.
ARCH Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/7/2023 | Series A | Bitterroot Bio | $145M | Yes | Alexandria Venture Investments, ARCH Venture Partners, Deerfield Management, Google Ventures, Koch Disruptive Technologies, and Undisclosed Investors | 3 |
5/26/2023 | Series B | Motion | $13.93M | Yes | 2 | |
5/18/2023 | Series A - II | Myeloid Therapeutics | $73M | Yes | 2 | |
5/16/2023 | Series C | |||||
5/12/2023 | Series D |
Date | 6/7/2023 | 5/26/2023 | 5/18/2023 | 5/16/2023 | 5/12/2023 |
|---|---|---|---|---|---|
Round | Series A | Series B | Series A - II | Series C | Series D |
Company | Bitterroot Bio | Motion | Myeloid Therapeutics | ||
Amount | $145M | $13.93M | $73M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Alexandria Venture Investments, ARCH Venture Partners, Deerfield Management, Google Ventures, Koch Disruptive Technologies, and Undisclosed Investors | ||||
Sources | 3 | 2 | 2 |
ARCH Venture Partners Portfolio Exits
114 Portfolio Exits
ARCH Venture Partners has 114 portfolio exits. Their latest portfolio exit was CERo Therapeutics on June 05, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
6/5/2023 | Acq - Pending | 2 | |||
10/20/2022 | IPO | Public | 18 | ||
6/15/2022 | Acquired | 1 | |||
Date | 6/5/2023 | 10/20/2022 | 6/15/2022 | ||
|---|---|---|---|---|---|
Exit | Acq - Pending | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 18 | 1 |
ARCH Venture Partners Acquisitions
1 Acquisition
ARCH Venture Partners acquired 1 company. Their latest acquisition was Caliper Life Sciences on May 01, 1998.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
5/1/1998 | Private Equity | $37.09M | Acquired |
Date | 5/1/1998 |
|---|---|
Investment Stage | Private Equity |
Companies | |
Valuation | |
Total Funding | $37.09M |
Note | Acquired |
Sources |
ARCH Venture Partners Fund History
16 Fund Histories
ARCH Venture Partners has 16 funds, including ARCH Venture Fund XII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
6/29/2022 | ARCH Venture Fund XII | $3,000M | 1 | ||
1/28/2021 | ARCH Venture Fund XI | $1,850M | 2 | ||
10/28/2019 | ARCH Venture Fund X | Early-Stage Venture Capital | Open | $636M | 3 |
10/25/2019 | ARCH Venture Fund X Overage | ||||
11/18/2016 | ARCH Venture Fund IX |
Closing Date | 6/29/2022 | 1/28/2021 | 10/28/2019 | 10/25/2019 | 11/18/2016 |
|---|---|---|---|---|---|
Fund | ARCH Venture Fund XII | ARCH Venture Fund XI | ARCH Venture Fund X | ARCH Venture Fund X Overage | ARCH Venture Fund IX |
Fund Type | Early-Stage Venture Capital | ||||
Status | Open | ||||
Amount | $3,000M | $1,850M | $636M | ||
Sources | 1 | 2 | 3 |
ARCH Venture Partners Partners & Customers
1 Partners and customers
ARCH Venture Partners has 1 strategic partners and customers. ARCH Venture Partners recently partnered with JW Group on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/13/2022 | Partner | United States | JW ties up with US venture capitalist for ‘R&D open innovation’ The JW Group partnered with U.S. venture capital ARCH Venture Partners to strengthen global open innovation . | 1 |
Date | 7/13/2022 |
|---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | JW ties up with US venture capitalist for ‘R&D open innovation’ The JW Group partnered with U.S. venture capital ARCH Venture Partners to strengthen global open innovation . |
Sources | 1 |
ARCH Venture Partners Team
13 Team Members
ARCH Venture Partners has 13 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Clinton W. Bybee | Founder | Current | |
Name | Clinton W. Bybee | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Compare ARCH Venture Partners to Competitors
Lightspeed Venture Partners operates as an early-stage venture capital firm. It focuses on accelerating disruptive innovations and trends in the enterprise and consumer sectors. It was founded in 2000 and is based in Menlo Park, California.
Sequoia is a venture capital firm. It seeks to invest in companies operating in the information technology, healthcare, manufacturing, mobile, nanotechnology, financial service, internet, energy, media, and retail sectors. The company was founded in 1972 and is based in Menlo Park, California.
Slow Ventures is an early-stage focused venture capital firm. The firm invests in companies operating in commercial products, commercial services, consumer services, financial services, pharmaceuticals, and other sectors. It was founded in 2011 and is based in San Francisco, California.
SyndicateRoom is an online equity crowdfunding platform that allows its members to co-invest in exciting companies with seasoned investors.
Osaka University Venture Capital (OUVC), associated with Osaka University, is focused on early-stage ventures in the fields of life innovation, green innovation, and platform technology.
Revolution is a venture capital firm. It makes seed, early-stage, and growth equity investments. It was founded in 2005 and is based in Washington, DC.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.